Complete financial analysis of Axonics, Inc. (AXNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axonics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Regulus Resources Inc. (RGLSF) Income Statement Analysis – Financial Results
- Mustek Limited (MST.JO) Income Statement Analysis – Financial Results
- Playfair Mining Ltd. (PLY.V) Income Statement Analysis – Financial Results
- IGM Financial Inc. (IGM.TO) Income Statement Analysis – Financial Results
- Tombola Gold Limited (TBA.AX) Income Statement Analysis – Financial Results
Axonics, Inc. (AXNX)
About Axonics, Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 366.38M | 273.70M | 180.29M | 111.54M | 13.82M | 707.00K | 128.12K | 0.00 |
| Cost of Revenue | 91.83M | 76.04M | 64.57M | 44.44M | 6.49M | 356.00K | 117.94K | 625.12K |
| Gross Profit | 274.55M | 197.67M | 115.72M | 67.09M | 7.33M | 351.00K | 10.17K | -625.12K |
| Gross Profit Ratio | 74.94% | 72.22% | 64.18% | 60.15% | 53.04% | 49.65% | 7.94% | 0.00% |
| Research & Development | 34.89M | 34.41M | 37.30M | 29.17M | 20.18M | 19.40M | 12.33M | 12.51M |
| General & Administrative | 45.75M | 40.24M | 32.79M | 25.55M | 19.08M | 9.36M | 4.82M | 4.46M |
| Selling & Marketing | 189.56M | 156.02M | 105.79M | 66.13M | 48.67M | 3.72M | 1.03M | 516.08K |
| SG&A | 235.32M | 196.26M | 138.57M | 91.68M | 67.75M | 13.09M | 5.85M | 4.97M |
| Other Expenses | 14.96M | 9.38M | 7.24M | -412.15K | 0.00 | 0.00 | -20.82K | -291.00 |
| Operating Expenses | 270.20M | 240.05M | 183.11M | 120.85M | 87.93M | 32.49M | 18.19M | 17.48M |
| Cost & Expenses | 392.44M | 316.09M | 247.68M | 165.30M | 94.42M | 32.84M | 18.30M | 17.48M |
| Interest Income | 17.31M | 5.13M | 40.00K | 761.00K | 2.97M | 998.00K | 200.58K | 84.02K |
| Interest Expense | 0.00 | 2.43M | 7.43M | 1.87M | 2.31M | 1.34M | 22.00K | 0.00 |
| Depreciation & Amortization | 12.49M | 12.72M | 10.13M | 2.64M | 1.59M | 946.00K | 725.39K | 625.12K |
| EBITDA | 7.78M | -47.16M | -61.73M | -51.30M | -78.03M | -31.19M | -17.33M | -16.77M |
| EBITDA Ratio | 2.12% | -10.18% | -33.34% | -47.52% | -561.69% | -4,404.38% | -13,479.81% | 0.00% |
| Operating Income | -26.06M | -42.39M | -67.39M | -53.76M | -80.60M | -32.14M | -18.17M | -17.48M |
| Operating Income Ratio | -7.11% | -15.49% | -37.38% | -48.20% | -583.21% | -4,545.54% | -14,185.62% | 0.00% |
| Total Other Income/Expenses | 17.31M | 2.63M | -7.48M | -1.15M | 665.00K | -345.00K | 114.33K | 82.93K |
| Income Before Tax | -8.74M | -62.32M | -79.29M | -54.91M | -79.93M | -32.48M | -18.06M | -17.40M |
| Income Before Tax Ratio | -2.39% | -22.77% | -43.98% | -49.23% | -578.39% | -4,594.34% | -14,097.05% | 0.00% |
| Income Tax Expense | -2.66M | -2.62M | 782.00K | 1.00K | 1.00K | 1.00K | -20.82K | -291.00 |
| Net Income | -6.09M | -59.70M | -80.07M | -54.92M | -79.94M | -32.48M | -18.06M | -17.40M |
| Net Income Ratio | -1.66% | -21.81% | -44.41% | -49.24% | -578.40% | -4,594.48% | -14,097.05% | 0.00% |
| EPS | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| EPS Diluted | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| Weighted Avg Shares Out | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
| Weighted Avg Shares Out (Dil) | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
Axonics to Participate in September Investor Conferences
Axonics Announces CFO Retirement and Appoints Successor
Why Shares of Axonics Rose Friday
Axonics, Inc. (AXNX) Q2 2023 Earnings Call Transcript
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
Axonics Reports Second Quarter 2023 Financial Results
Axonics to Report Second Quarter 2023 Financial Results on July 27
Axonics, Inc. (AXNX) Q1 2023 Earnings Call Transcript
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
Axonics Reports First Quarter 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports